Pharmaceuticals – a recap Discuss the view that “drugs companies are not fully addressing the needs of the world’s poorest people.”

Slides:



Advertisements
Similar presentations
Impact of JUSFTA on affordability and availability of medicines from perspective of local generic manufacturers Towards equitable and affordable medicine.
Advertisements

1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Overview of the medicine prices and availability survey methodology Presentation template for adaptation and use in medicine prices and availability survey.
Differential Pricing: Reconciling R&D, IP and Access Patricia M. Danzon PhD The Wharton School University of Pennsylvania.
Pharmaceuticals Industry Research and Development.
Understanding patents & medicine access the WTO, free trade agreements & patent law.
Pharmaceutical Companies Should do a Better Job Providing AIDS Treatment A Presentation by: Greg Sorrells Julieth Monroy Julieth Monroy and Rachel Kohn.
Efficiency, Ethics and Cost in Pharmaceutical Research and Manufacturing Matthew Wirtala Spring 2006.
Healthcare Reforms That Might Work Sam Clovis, Jr. Doctor of Public Administration Morningside College.
Trade-Offs by Harold Winter
Access to medicines – Barriers relating to intellectual property rights and data exclusivity Julian Cockbain & Sigrid Sterckx Yale conference Human rights.
Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.
EXAMPLES OF CREATIVE CAPITALISM IN ACTION. SIMPLE CORPORATE PHILANTHROPY: CORPORATIONS GIVE AWAY GOODS OR CASH TO PEOPLE WHO DESPERATELY NEED IT. Pro:
Elizabeth Davis Department of Pharmacology Monash University, Australia Drugs & Society a new introductory unit in pharmacology.
Lecture 9 Tuesday, October 2 Healthcare and the Market.
Issues facing Australia’s health system CHAPTER 10.
Medicine Access: Claims & Data Sanjay Basu. The Framework for Access The pipeline fallacy Patents and pricing.
© 2006 McGraw-Hill Ryerson Limited. All rights reserved.1 Chapter 11: Monopoly Prepared by: Kevin Richter, Douglas College Charlene Richter, British Columbia.
DAVID HARDING CPhI 2008 SHANGHAI JUNE 24–26, 2008 Product Selection for API Manufacturers and Generic Pharmaceutical Companies: A Tool for Success.
More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Did you know...  That one in every six people on this globe suffers from a disease of poverty?  That ten million people die each year from diseases.
Pharmaceuticals: Lecture Outline Introduction 1.Historical Development of Pharmaceuticals 2. Modern Uses & Canadian Health Care 3. Doctors & Pharmaceuticals.
Authorized Generics: Good For Everyone (Even Generics) Jerome A. Swindell Senior Counsel.
A very short introduction to patents & access to medicines.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Restrictions on exports of medicine: irrational public policy, backdoor efforts to marginalize compulsory licensing, or Northern protectionism? James Love.
 .
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
SWITCHING OF MEDICINES 19 June SWITCH Reclassification of legal status of a medicine Typically one with many years of experience of safe use From.
THE UK EXPERIENCE RELATED TO CASE C- 185/10, COMMISSION v REPUBLIC OF POLAND DOES A “SPECIAL NEED” ARISE FOR AN UNLICENSED MEDICINE IF THE LICENSED EQUIVALENT.
McGraw-Hill/Irwin © 2002 The McGraw-Hill Companies, Inc., All Rights Reserved. Chapter 20 Health Care.
A L ESSON IN H EALTH E CONOMICS C HAPTER 13 Code Blue Health Science Edition 4.
INTELLECTUAL PROPERTY RIGHTS
Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.
ANNOUNCEMENTS 1.New Chapter on Finance is available at 2.Updated chapters on Healthcare and the Environment also available at 3.All.
An Alternative to Pharmaceutical Patents Christian Engström Vice Chairman, The Swedish Pirate Party.
4. Access to medication & healthcare Learning objectives: - to identify the why many people cannot access medication - to understand how NGOs and the UN.
Patent: (KR ) COAGULATING AGENT FOR THE TOTAL PHOSPHORUS ELIMINATING AGENT OF A SEWAGE TREATING PLANT AND A METHOD FOR PREPARING THE SAME CAPABLE.
Owen Smith – World Bank Washington DC – February 1 st, 2011 Health care financing in Georgia.
Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
Pharmaceutical Business Case Study (This case study was prepared by MBA-Ex Batch 11, Wayne Chavit & Karl Quipanes Students of Dr. Long Manalo at the Southwestern.
Ellen ‘t Hoen Médecins sans Frontières
Team Constellation Warner Chilcott DRAFT COPY.  Pharmaceutical products in women's healthcare & dermatology  Perishable in both the physical and intellectual.
Human Needs. Which needs are most important? #5 #4 #3 #2 Most Important.
PRIORITIZING HEALTH IN U.S. TRADE POLICY: A CASE EXAMPLE.
Tensions between Brazil and the United States
If I ’ m a the boss of Trans- National Corporate (TNC) …… -What is WTO By Suzanne Wu (Hong Kong Peoples ’ Alliance on WTO, HKPA)
The World Trade Organisation. What is the WTO?  Multilateral body responsible for overseeing the conduct of international trade.
Health and Wealth Revision. Topics to focus on Services provided by NHS Inequalities in health Government –ways of improving health in Scotland Causes.
A Market for Vaccines Xavier Sala-i-Martin Columbia University November 2005.
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.
Gene Therapy By: Destiny Osborne & Amanda Owens. Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future,
PRIVATISATION PRIVATISATION. PRIVATISATION, NATIONALISATION OR DENATIONALISATION?  _______________________ – the act of putting a nationalised industry.
A Market for Vaccines Xavier Sala-i-Martin. Recall AIDS Fund (AIDS Fund) Governments of Rich Countries contribute to a fund The money is spent to buy.
BUS 235 AID Peer Educator/ bus235aid.com FOR MORE CLASSES VISIT
Positions of pharmaceutical companies Analysis of the websites of the three world’s largest PCs: Pfizer, Roche and Novartis.
TRADE NEGOTIATION ON PHARMACETICALS PRESENTED BY CHOGO,MALESO (092SIS10).
Difference between globalization and modernization “Modernization is a choice made by a less-advanced group of people to take advantage of their choice.
ANTI COUNTERFEIT FROM COMMUNITY PERSPECTIVE -Estimates indicates 30% of drugs in Kenyan market are fake. -40 billion lost every year due to counterfeit.
International Aid lesson 1
Intellectual Property Protection and Access to Medicines
Learning Area 1 Information And Communication Technology and Society
Fifth Annual Pharmaceutical Regulation & Compliance Congress
The Major Criticism of this Theory
Law of Intellectual Property Rights
Pharmaceuticals Industry
Presentation transcript:

Pharmaceuticals – a recap Discuss the view that “drugs companies are not fully addressing the needs of the world’s poorest people.”

How do pharmaceuticals make their money? Branded drugs can be 30x more expensive than generic drugs, even though they are the same

Research and Development Most money is spent on diseases of affluence. If a new treatment is developed it is considered intellectual property so it is illegal to make generic copies for 20 years

Consumers have little choice about which drugs they take. They take the drugs prescribed by their doctor Therefore, the pharmaceutical industry targets marketing at doctors In the USA, the government is prevented from encouraging the use of generic drugs due to legal action by the Pharmaceutical Manufacturing Association

DEBATE TIME Team ATeam B

You have 15 mins to prepare Use the cards to formulate your arguments Use web resources to gain useful stats to back up your arguments Use your own knowledge and understanding to counter argue against the other team. You will have 2 min to speak and then 1 min to respond to arguments

NOYES Unless controlled, the generic drugs business will inevitably undermine research and development into new drugs Millions die each year from preventable, treatable diseases. It is immoral to deny them access to the cheapest drugs The problem is poverty not the high cost of patented drugs. Most poor nations cannot even afford the cost of generic drugs Poor nations should not have to foot the bill for research and development into drugs aimed at richer nations The drugs industry is a commercial business not a charity. If we were to subsidise the poor, the taxpayer would foot the bill. Allowing poorer countries to undercut patent medicine prices will have minimal effect on the profits of the drugs industry